Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

b-Catenin (CTNNB1)

In vitro and cell culture studies identified a CTNNB1 antagonist that could help treat wingless-type MMTV integration site (WNT) and CTNNB1-driven cancers. A stapled peptide, identified by a combination of structure-based design and directed evolution, bound CTNNB1 at a coactivator recruitment site with nanomolar affinity. In colorectal cancer cell lines driven by WNT and CTNNB1 signaling, the stapled peptide decreased cell proliferation compared with an inactive control peptide. Next steps could include testing the efficacy of the stapled peptide in vivo.

SciBX 5(44); doi:10.1038/scibx.2012.1155
Published online Nov. 8, 2012

Patent and licensing status unavailable

Grossmann, T.N. et al. Proc. Natl. Acad. Sci. USA; published online
Oct. 15, 2012;
doi:10.1073/pnas.1208396109
Contact: Gregory L. Verdine,
Harvard University, Cambridge, Mass.
e-mail:
gregory_verdine@harvard.edu